| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-24863 | |||
| BSA Free | NBP2-24729SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-24875SS | |||
| Azide and BSA Free | NBP2-33263 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-39002SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB100-56726 | |||
| BSA Free | NB100-56722SS | |||
| Azide and BSA Free | NB100-56726SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-19371SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-76769SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-76701SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| IHC-Prediluted | NBP2-44513 | |||
| Azide and BSA Free | NBP2-34569-0.1mg | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 488 | DDX0700A488-100 | |||
| Alexa Fluor 546 | DDX0700A546-100 | |||
| Alexa Fluor 647 | DDX0700A647-100 | |||
![Simple Western: TLR9 Antibody (26C593.2) [NBP2-24729] - Lane view shows a specific band for TLR9 in 0.5 mg/ml of Ramos lysate. This experiment was performed under reducing conditions using the 66-440 kDa separation system. Image using the Azide Free format of this antibody.](http://images.novusbio.com/fullsize/TLR9-Antibody-26C593-2-Simple-Western-NBP2-24729-img0029.jpg "Simple Western: TLR9 Antibody (26C593.2) [NBP2-24729] - Lane view shows a specific band for TLR9 in 0.5 mg/ml of Ramos lysate. This experiment was performed under reducing conditions using the 66-440 kDa separation system. Image using the Azide Free format of this antibody.")
![Flow Cytometry: TLR9 Antibody (26C593.2) [NBP2-24729] - Expression of TLR9 protein on epithelial cells. HNEC, Detroit-562 and FaDu were stained intracellularly with PE-Ab against TLR9 (open histograms) or appropriate isotype control (shaded histograms) and analyzed by flow cytometry. Representative pictures from one out of three independent experiments are shown. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0098239), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR9-Antibody-26C593-2-Flow-Cytometry-NBP2-24729-img0025.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: TLR9 Antibody (26C593.2) [NBP2-24729] - Expression of TLR-9 protein in HB cells before and after 48 hr of transfection. Beta-actin was used as an internal control. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0092748) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR9-Antibody-26C593-2-Knockdown-Validated-NBP2-24729-img0031.jpg)
![Flow Cytometry: TLR9 Antibody (26C593.2) [NBP2-24729] - Analysis of colonic LP or peritoneal cavity (PerC) of normal mice were evaluated by flow cytometry. B cells were intracellularly stained with the anti-TLR9 antibody after the cell surface staining with anti-B220 and CD5 antibodies, and examined using flow cytometry. N = 3, performed twice. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0146191) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR9-Antibody-26C593-2-Flow-Cytometry-NBP2-24729-img0027.jpg)
![Immunocytochemistry/Immunofluorescence: TLR9 Antibody (26C593.2) [NBP2-24729] - Cbl-b is required for the endocytic transit of TLR9. Representative confocal microscopic images of splenocytes from mice with indicated genotypes. For experiments, cells were stimulated through the BCR (green) for 30 minutes then fixed and stained for TLR9 (blue) and Lamp-1 (red)(n = 3). Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0089792) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR9-Antibody-26C593-2-Immunocytochemistry-Immunofluorescence-NBP2-24729-img0032.jpg)
![Immunohistochemistry-Paraffin: TLR9 Antibody (26C593.2) [NBP2-24729] - Monkey retina tissue. Image from verified customer review.](http://images.novusbio.com/fullsize/TLR9-Antibody-26C593-2-Immunohistochemistry-Paraffin-NBP2-24729-img0023.jpg)
![Flow Cytometry: TLR9 Antibody (26C593.2) [NBP2-24729] - Gating strategy for the detection of TLR-7 and -9 in B cell subsets. PBMC were isolated from whole blood and stained for surface markers before cells were fixed, permeabilised and stained for TLR-9. FSC and SSC were first used to gate out debris and SSC-A and SSC-H was utilized to eliminate duplicates. Further gating was done on CD45 and CD19, to target B cells. To separate between the different B cell populations, we gated on CD27 and IgD (D), followed by TLR-9 expression on these subsets. Data from one representative patient is shown. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0120383) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR9-Antibody-26C593-2-Flow-Cytometry-NBP2-24729-img0028.jpg)
![Western Blot: TLR9 Antibody (26C593.2) [NBP2-24729] - Analysis of TLR9 in A) human PBMC, B) human intestine, C) mouse intestine, and D) rat intestine tissue lysates using this antibody at a dilution of 3 ug/ml.](http://images.novusbio.com/fullsize/TLR9-Antibody-26C593-2-Western-Blot-NBP2-24729-img0033.jpg)
![Flow Cytometry: TLR9 Antibody (26C593.2) [NBP2-24729] - Expression of TLR9 on turbinate epithelial cells from healthy controls compared to turbinate and polyp epithelial cells from patients with CRSwNP, n = 5 (A). Intracellular staining for TLR9 (open histogram, black line) and isotype control (filled histogram) on turbinate epithelial cells from a healthy control (B), turbinate epithelial cells (C) and polyp epithelial cells from a patient (D), analysed using flow cytometry. Results are presented as mean +/- SEM, **P<0.01. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0105618) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR9-Antibody-26C593-2-Flow-Cytometry-NBP2-24729-img0030.jpg)
![Flow Cytometry: TLR3 Antibody (40C1285.6) [NBP2-24875] - Expression of TLR3 protein on epithelial cells. HNEC (A), Detroit-562 (B) and FaDu (C) were stained intracellularly with FITC-Abs against TLR3 (open histograms) or appropriate isotype control (shaded histograms) and analyzed by flow cytometry. Representative pictures from one out of three independent experiments are shown. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0098239), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR3-Antibody-40C1285-6-Flow-Cytometry-NBP2-24875-img0014.jpg "Flow Cytometry: TLR3 Antibody (40C1285.6) [NBP2-24875] - Expression of TLR3 protein on epithelial cells. HNEC (A), Detroit-562 (B) and FaDu (C) were stained intracellularly with FITC-Abs against TLR3 (open histograms) or appropriate isotype control (shaded histograms) and analyzed by flow cytometry. Representative pictures from one out of three independent experiments are shown. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0098239), licensed under a CC-BY license.")
![Western Blot: TLR3 Antibody (40C1285.6) [NBP2-24875] - All the cell lines displayed a strong expression of TLR3 protein. Cell lysates were electrophoresed and blotted to PVDF membrane, which was probed with TLR3-specific antibody. To confirm the immunoreactivity of the antibody, different positive controls were included. Beta-actin was served as loading control and was used to normalize expression levels between cells. Data are representative for analysis of >=2 independent experiments. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0060671) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR3-Antibody-40C1285-6-Western-Blot-NBP2-24875-img0015.jpg)
![Immunohistochemistry-Paraffin: TLR3 Antibody (40C1285.6) [NBP2-24875] - Mouse colon using TLR3 antibody (clone 40C1285.6) at 1:500 dilution with HRP-DAB detection and hematoxylin counterstaining. Intense signal was found in subset of cells at the bases of the crypts.](http://images.novusbio.com/fullsize/TLR3-Antibody-40C1285-6-Immunohistochemistry-Paraffin-NBP2-24875-img0006.jpg)
![Flow Cytometry: TLR3 Antibody (40C1285.6) [NBP2-24875] - Expression of TLR3 in Fravel, L363, OPM1, RPMI8226, XG1, and NCI-H929 as determined by flow cytometry. HCMLs were stained using an intracellular staining protocol with TLR3 antibodies followed by relevant secondary fluorescent-conjugated antibodies. Filled histograms (purple) represent the isotype controls and the open histograms (red) indicate TLR3. Data are representative for analysis of >=2 independent experiments. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0060671) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR3-Antibody-40C1285-6-Flow-Cytometry-NBP2-24875-img0016.jpg)
![Western Blot: TLR3 Antibody (40C1285.6) [NBP2-24875] - Analysis of TLR3 in lysates from A) human intestine and F) ovary using TLR3 antibody at 3 ug/ml. Goat anti-mouse HRP conjugate was used as secondary.](http://images.novusbio.com/fullsize/TLR3-Antibody-40C1285-6-Western-Blot-NBP2-24875-img0018.jpg)
![Western Blot: TLR3 Antibody (40C1285.6) [NBP2-24875] - HEK293T cells were transfected with TLR3, TLR3-9-3 and TLR3-3-9. Western blot was performed using anti-TLR3 or anti-HA antibodies. Anti-Beta-actin antibodies were used as a loading control. The representative data from three experiments are shown. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0092391) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR3-Antibody-40C1285-6-Western-Blot-NBP2-24875-img0017.jpg)
![Immunohistochemistry-Paraffin: TLR3 Antibody (40C1285.6) [NBP2-24875] - Tissue section of mouse intestine using TLR3 antibody (clone 40C1285.6) at 1:500 dilution with HRP-DAB detection and hematoxylin counterstaining. The representative image shows a punctate staining of the ER and endosomes in a subset of cells in Peyer's patches (organized lymphoid nodules) in the tested section.](http://images.novusbio.com/fullsize/TLR3-Antibody-40C1285-6-Immunohistochemistry-Paraffin-NBP2-24875-img0007.jpg)
![Immunohistochemistry-Paraffin: TLR3 Antibody (40C1285.6) [NBP2-24875] - Analysis of TLR3 in (A) human gut lumen (longitudinal section, transverse region) using this antibody at 10 ug/ml (Data courtesy Dr. Elizabeth Furrie, University of Dundee) and mouse spleen tissue using isotype control (B) and this antibody (C) at 5 mg/ml.](http://images.novusbio.com/fullsize/TLR3-Antibody-40C1285-6-Immunohistochemistry-Paraffin-NBP2-24875-img0002.jpg)
![Immunohistochemistry: TLR3 Antibody (40C1285.6) - BSA Free [NBP2-24875] - The nasal epithelium expresses TLR3, TLR7, TLR9, RIG-I & MDA-5.Sections of nasal biopsies were incubated with antibodies against TLR3 (A), TLR7 (B), TLR9 (C), RIG-I (D), & MDA-5 (E) & visualized by 3, 3′-diaminobenzidine (brown). In control slides (F), N-series universal negative control reagent was used. All sections were accompanied with a square magnification. All slides were counterstained with haematoxylin (blue). The figure shows one representative biopsy out of four (3 male, 1 female). The arrows indicate positive stained cells. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24886842), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-24875_mouse-monoclonal-tlr3-antibody-40c1285-6-310202415384128.jpg)
![Immunohistochemistry: TLR3 Antibody (40C1285.6) - BSA Free [NBP2-24875] - TLRs are expressed & functional in chondrocytes.A RT-PCR for TLR3 & 9 expression in primary human & murine chondrocytes. GAPDH served as loading control. B Confocal microscopy of labelled CpG (green) & poly(I:C) (red) uptake by either primary human chondrocytes (scale bar 20 µm) or murine hip caps (scale bar 50 µm (centre) 20 µm (right)). DAPI (blue) was used as counterstaining for nuclei. C IFN alpha ELISA of murine chondrocytes stimulated with ODN (one-way ANOVA:F (2, 9) = 2.21, p = 0.16, N = 4). D IFN alpha ELISA of primary human chondrocytes stimulated with ODN & poly(I:C) (one-way ANOVA:F (3, 11) = 0.75, p = 0.55, N = 4). E IFN beta ELISA of murine chondrocytes stimulated with poly(I:C) or ODN (one-way ANOVA: F (2, 15) = 59.61, p < 0.0001, N = 6). F IFN beta ELISA of primary human chondrocytes stimulated with poly(I:C) or ODN (one-way ANOVA:F (2, 6) = 95.43, p = <0.0001, N = 3). G Staurosporine was used to induce cell death. The release of RNA from human primary chondrocytes after treatment was measured in the culture supernatant using the RiboGreen assay (RM ANOVA: F (4, 12) = 101.2, p < 0.0001, N = 4). Dunnett’s post-hoc test revealed an increase for 200, 500, & 1000 ng/ml staurosporine treatment compared to the untreated control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35277480), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-24875_mouse-monoclonal-tlr3-antibody-40c1285-6-31020241611475.jpg)
![Western Blot: TLR3 Antibody (40C1285.6) - BSA Free [NBP2-24875] - TLR mRNA & protein expression in airlifted immortal human corneal (HCET) & conjunctival epithelial cells (IOBA-NHC). (a) Averaged fold increase of TLR mRNA in IOBA-NHC cells. The increase was statistically significant for each TLR. (b) Averaged fold increase of TLR mRNA in HCET cells. The increase was statistically significant for each TLR. Cells were airlifted for 10 days. TLR mRNA level was determined by qPCR & compared to submerged cells. The experiment was repeated 3 times. Y error bars represent the standard deviation of the averaged results. (c) Micrographs of a representative western blot showing TLR protein expression in IOBA-NHC cells. Lane 1: submerged-cultured; lane 2: 3 days after airlifting culture; lane 3: 7 days after airlifting culture; lane 4: 10 days after airlifting culture. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) protein was probed as loading control. (d) Averaged TLR protein increase in IOBA-NHC cells 10 days after airlifting culture compared to submerged-cultured cells. X-ray films from 2 independent western blot experiments were scanned in a densitometer, & the results were averaged. The increase was statistically significant for each TLR protein tested. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24976686), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-24875_mouse-monoclonal-tlr3-antibody-40c1285-6-310202416113516.jpg)
![Immunohistochemistry-Paraffin: FoxP3 Antibody [NB100-39002] - Mouse spleen stained with FoxP3 antibody. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunohistochemistry-Paraffin-NB100-39002-img0011.jpg "Immunohistochemistry-Paraffin: FoxP3 Antibody [NB100-39002] - Mouse spleen stained with FoxP3 antibody. IHC-P image submitted by a verified customer review.")
![Immunohistochemistry-Paraffin: FoxP3 Antibody [NB100-39002] - Number of Granzyme B+ and FoxP3+ cells infiltrating tumors. Representative images of IHC staining of FoxP3+ and Granzyme B+ cells in the peri-tumoral areas in two mice characterized by low FoxP3+ and high Granzyme B+ (panels 1 and 2) or high FoxP3+ and low Granzyme B+ (panels 3 and 4). Image collected and cropped by Citeab from the following publication (Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting. Oncotarget (2018) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunohistochemistry-Paraffin-NB100-39002-img0025.jpg)
![Immunohistochemistry: FoxP3 Antibody [NB100-39002] - CCR10-expressing CD4+CD25+FOXP3+ Treg cells are enriched in the spinal cord after SCI. Double immunostaining of FOXP3 (red) and CCR10 (green) in the spinal cord sections after sham or SCI surgery. The merged images are also shown. Arrows indicate cells with positive staining and colocalization. Scale bar, 100 i1/4m. Data are mean A+- SD. Image collected and cropped by Citeab from the following publication (CCL28 promotes locomotor recovery after spinal cord injury via recruiting regulatory T cells. Aging (Albany NY) (2019) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunohistochemistry-NB100-39002-img0027.jpg)
![Flow Cytometry: FoxP3 Antibody [NB100-39002] - An intracellular stain was performed on SK-MEL-28 cells with NB100-39002 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Flow-Cytometry-NB100-39002-img0022.jpg)
![Immunohistochemistry-Paraffin: FoxP3 Antibody [NB100-39002] - Tissue section of human tonsil using 1:200 dilution of rabbit anti-FoxP3 antibody. The staining was developed with HRP-labeled anti-rabbit IgG secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin. This FoxP3 antibody generated an expected and a specific nuclear staining of FOXP3 in a subset of cells which are potentially the Treg cells.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunohistochemistry-Paraffin-NB100-39002-img0017.jpg)
![Immunohistochemistry: FoxP3 Antibody [NB100-39002] - Antibody was tested in mouse spleen using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunohistochemistry-NB100-39002-img0014.jpg)
![Immunohistochemistry-Paraffin: FoxP3 Antibody [NB100-39002] - FFPE bovine spleen tissue. Deparaffinization and antigen retrieval was carried out with PTlink from Dako, citrate buffer pH 6. Anti-Foxp3 antibody was used at a 1:100 dilution. Secondary reagent: Envision, from Dako. Staining: DAB and hematoxylin. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunohistochemistry-Paraffin-NB100-39002-img0024.jpg)
![Western Blot: FoxP3 Antibody [NB100-39002] - Jurkat Tag cells were transfected with the expression vector (vector) or with the Foxp3 expression construct (Foxp3). 24 hours after transfection, cells were lysed and analyzed by Western blot with anti-Foxp3 antiserum (1:2000 dilution).](http://images.novusbio.com/fullsize/FoxP3-Antibody-Western-Blot-NB100-39002-img0018.jpg)
![Immunocytochemistry/Immunofluorescence: FoxP3 Antibody [NB100-39002] - Transfectants were stained with anti-Foxp3 antibody and HRPO-conjugated (upper panel) or Cy3-conjugated (lower panels) secondary antibody. Representative images (x100) are shown.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunocytochemistry-Immunofluorescence-NB100-39002-img0012.jpg)
![Immunohistochemistry-Paraffin: FoxP3 Antibody [NB100-39002] - Tissue section of human tonsil using 1:200 dilution of rabbit anti-FoxP3 antibody. The staining was developed with HRP-labeled anti-rabbit IgG secondary antibody and DAB reagent, and nuclei of cells were counterstained with hematoxylin. This FoxP3 antibody generated an expected and a specific nuclear staining of FOXP3 in a subset of cells which are potentially the Treg cells.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunohistochemistry-Paraffin-NB100-39002-img0015.jpg)
![Flow Cytometry: FoxP3 Antibody [NB100-39002] - Transfectants were permeabilized and stained with anti-Foxp3 antibody and FITC-conjugated secondary antibody. Cells were analyzed by flow cytometry. Percentage of positively stained cells are shown.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Flow-Cytometry-NB100-39002-img0013.jpg)
![Flow Cytometry: FoxP3 Antibody [NB100-39002] - An intracellular stain was performed on MCF7 cells with FoxP3 Antibody NB100-39002PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Flow-Cytometry-NB100-39002-img0021.jpg)
![Dual RNAscope ISH-IHC: FoxP3 Antibody [NB100-39002] - CD8A mRNA (red) and FOXP3 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human breast cancer. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-CD8A and FoxP3 antibody at 1:400 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/FoxP3-Antibody-Dual-RNAscope-ISH-IHC-NB100-39002-img0028.jpg)
![Dual RNAscope ISH-IHC: FoxP3 Antibody [NB100-39002] - CD4 mRNA (red) and FOXP3 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human breast cancer. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-CD4 and FOXP3 antibody at 1:200 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/FoxP3-Antibody-Dual-RNAscope-ISH-IHC-NB100-39002-img0029.jpg)
![Immunocytochemistry/ Immunofluorescence: FoxP3 Antibody - BSA Free [NB100-39002] - CCR10-expressing CD4+CD25+FOXP3+ Treg cells are enriched in the spinal cord after SCI. (A, B) Representative flow cytometry dot plots (A) & percentage (B) of CD4+CD25+FOXP3+ cells among the CD4+ T cells in the spinal cord after sham or SCI surgery. Cells were gated on 7-AAD negative population & the numbers inside plots refer to % Treg cells (n=5). (C, D) Representative histogram of CCR10 (C) & CCR3 (D) expression in CD4+CD25+FOXP3+ cells as gated in (A). (E) CD4+CD25+FOXP3+ cells in the spinal cord from sham & SCI mice were sorted out & analyzed by Western blotting to detect the expression of CCR10 & CCR3. GAPDH was used as a loading control. (F) Double immunostaining of FOXP3 (red) & CCR10 (green) in the spinal cord sections after sham or SCI surgery. The merged images are also shown. Arrows indicate cells with positive staining & colocalization. Scale bar, 100 μm. Data are mean ± SD. The statistical analysis was performed using Student’s t-test. **, P<0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31557129), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-39002_rabbit-polyclonal-foxp3-antibody-310202415541911.jpg)
![Immunocytochemistry/ Immunofluorescence: FoxP3 Antibody - BSA Free [NB100-39002] - Effects of anaphylatoxins on transcription factor phosphorylation in ARPE-19 cells. (A–C) Protein phosphorylation of (A) CREB (Ser133); (B) FoxP3 (Ser418); & (C) FOXO1 (Ser256) was examined in ARPE-19 cells treated with C3a, C5a, or the combination of C3a/C5a at 1, 5, 10, & 15 min. Phosphorylation levels were normalized to beta -actin (relative p-protein levels), & slopes of the time course were determined. Anaphylatoxins were applied at concentrations of 300 nM (C3a) & 50 nM (C5a). Data are mean + SEM, n = 3, *p < 0.05, ***p < 0.001 (Student’s t-test). (D) Immunofluorescence staining of FoxP3. Upper panel: Lewis rat (albino) eye with experimental uveitis; lower panel: normal rat eye. Asterisks mark immune cells infiltrating the retina from the choroid through the retinal pigment epithelium (RPE) in the eye with uveitis (clinical score of 2, histological score of 1). Image collected & cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fimmu.2017.00703/full), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-39002_rabbit-polyclonal-foxp3-antibody-31020241554547.jpg)
![Flow Cytometry: TLR2 Antibody (TL2.1) [NB100-56722] - Analysis using the FITC conjugate of NB100-56726. Surface staining of stable HEK293/hTLR2 cells (IML-202, red) and vector control cells (IML-200, green) using TLR2 antibody at 1 ug/10^6 cells.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Flow-Cytometry-NB100-56722-img0005.jpg "Flow Cytometry: TLR2 Antibody (TL2.1) [NB100-56722] - Analysis using the FITC conjugate of NB100-56726. Surface staining of stable HEK293/hTLR2 cells (IML-202, red) and vector control cells (IML-200, green) using TLR2 antibody at 1 ug/10^6 cells.")
![Western Blot: TLR2 Antibody (TL2.1) [NB100-56722] - Expression of TLR2 was determined by western blotting. The immunoreactivity of the anti-TLR2 was confirmed with human intestinal lysate. Data are representative for analysis of >=2 independent experiments. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0060671) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Western-Blot-NB100-56722-img0015.jpg)
![Western Blot: TLR2 Antibody (TL2.1) [NB100-56722] - Total protein from human THP-1 and U937 cells was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-TLR2 (NB100-56722) in 5% BSA-TBST and detected with an anti-mouse HRP secondary antibody using NovaLume chemiluminescence detection reagent (NPB2-61915).](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Western-Blot-NB100-56722-img0016.jpg)
![Flow Cytometry: TLR2 Antibody (TL2.1) [NB100-56722] - Monitoring of TLR2 expression in normal B cells and primary MCL cells cultured for 24h in the absence/presence of CD40L, IL-4, and TLR ligands. Filled curves refer to isotypic control, empty curves to the TLR2 antibody (NB100-56722) of untreated samples. Dotted histograms represent CD40L+IL4 activated cells, dashed curves indicate CD40L+IL4 activated cells further treated with TLR ligands. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0153823) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Flow-Cytometry-NB100-56722-img0013.jpg)
![Flow (Cell Surface): TLR2 Antibody (TL2.1) [NB100-56722] - Flow (Cell Surface): - Azide Free [NB100-56726] - Analysis using the PE conjugate of NB100-56726. Staining of TLR2 on stable transfected cell line using this antibody at 1 ug/10^6 cells. Green: isotype control. Red: anti-TLR2 antibody. Image using the Azide Free form of this antibody.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Flow-Cell-Surface-NB100-56722-img0010.jpg)
![Block/Neutralize: TLR2 Antibody (TL2.1) [NB100-56722] - Human monocyte-derived DCs were pre-incubated wit TLR-neutralizing antibodies including TLR2 antibody (NB100-56722) for 1 h. Afterwards, DCs were infected with H. pylori G27 (MOI 5) and the levels of the costimulatory molecule CD86 and the maturation marker CD83 were analyzed by FACS on CD11c+ cells 24 h post-infection. Data are presented as mean +/- SD of five independent experiments. *p<=0.05, **p<=0.005, ***p<=0.0005. Asterisks on top of bars indicate significance relative to non-neutralized, H. pylori-primed control cells. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0104804) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Block-Neutralize-NB100-56722-img0014.jpg)
![Flow Cytometry: TLR2 Antibody (TL2.1) - BSA Free [NB100-56722] - Intracellular flow analysis of TLR2 in 1x10^6 PBMCs using 2 ug of NB100-56722. Shaded histogram represents cells without antibody; green represents isotype control; purple represents anti-TLR2 antibody.](http://images.novusbio.com/fullsize/nb100-56722_mouse-monoclonal-tlr2-antibody-tl2-1-17720241003212.jpg)
![Immunohistochemistry: CD4 Antibody [NBP1-19371] - Increased CD3+ and CD4+ T-cell occurrence in the brainstem of SHR-72 transgenic rat model for tauopathies. (A-D) Immunofluorescence staining showed CD4+ T-cells in SHR-72 transgenic animals. (E- H) Immunofluorescence staining showed more perivascular than brain parenchyma infiltrating CD4+ T-cells in SHR-72 transgenic animals. PLoS One. 2019 May 23;14(5):e0217216. doi: 10.1371/journal.pone.0217216.](http://images.novusbio.com/fullsize/CD4-Antibody-Immunohistochemistry-NBP1-19371-img0017.jpg "Immunohistochemistry: CD4 Antibody [NBP1-19371] - Increased CD3+ and CD4+ T-cell occurrence in the brainstem of SHR-72 transgenic rat model for tauopathies. (A-D) Immunofluorescence staining showed CD4+ T-cells in SHR-72 transgenic animals. (E- H) Immunofluorescence staining showed more perivascular than brain parenchyma infiltrating CD4+ T-cells in SHR-72 transgenic animals. PLoS One. 2019 May 23;14(5):e0217216. doi: 10.1371/journal.pone.0217216.")
![Immunohistochemistry: CD4 Antibody [NBP1-19371] - DBZ inhibits the accumulation of CD4+ T cells and Th2 differentiation in the AAAs. (B) The representation of immunohistochemical staining for CD4+ in abdominal aorta from four groups (left). Bar graphs show the percentage of CD4+ positive cell areas (right; n=3 per group). Bar: 50 um.](http://images.novusbio.com/fullsize/CD4-Antibody-Immunohistochemistry-NBP1-19371-img0018.jpg)
![Western Blot: CD4 Antibody [NBP1-19371] - CD4 antibody was tested in the following cell lysates: 1) human spleen 2) human tonsil 3) human placenta 4) human kidney 5) human liver 6) mouse spleen 7) mouse placenta 8) rat placenta.](http://images.novusbio.com/fullsize/CD4-Antibody-Western-Blot-NBP1-19371-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: CD4 Antibody [NBP1-19371] - CD4 antibody was tested in Jurkat cells with DyLight 488 (green). Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/CD4-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-19371-img0005.jpg)
![Flow Cytometry: CD4 Antibody - BSA Free [NBP1-19371] - An intracellular stain was performed on U-251 MG cells with CD4 Antibody NBP1-19371AF594 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 594.](http://images.novusbio.com/fullsize/CD4-Antibody---BSA-Free-Flow-Cytometry-NBP1-19371-img0023.jpg)
![Western Blot: CD4 Antibody [NBP1-19371] - Mouse spleen, 25ug total protein. Image from verified customer review.](http://images.novusbio.com/fullsize/CD4-Antibody-Western-Blot-NBP1-19371-img0007.jpg)
![Immunohistochemistry-Paraffin: CD4 Antibody [NBP1-19371] - Staining of paraffin-embedded mouse brain tissue. Photo courtesy of product review by verified customer.](http://images.novusbio.com/fullsize/CD4-Antibody-Immunohistochemistry-Paraffin-NBP1-19371-img0006.jpg)
![Immunohistochemistry-Paraffin: CD4 Antibody [NBP1-19371] - Analysis of a FFPE tissue section of mouse brain using CD4 antibody at 1:300 dilution with HRP-DAB detection and hematoxylin counterstaining. The antibody primarily generated a strong signal in the membranes of a subset of cells in the tested section.](http://images.novusbio.com/fullsize/CD4-Antibody-Immunohistochemistry-Paraffin-NBP1-19371-img0011.jpg)
![Immunohistochemistry-Paraffin: CD4 Antibody [NBP1-19371] - Analysis of a FFPE section of mouse spleen using CD4 antibody at 1:300 dilution with HRP-DAB detection and hematoxylin counterstaining. The antibody generated a strong signal in the membranes of a subset of cells in the spleen section and the staining showed punctate appearance in some cells.](http://images.novusbio.com/fullsize/CD4-Antibody-Immunohistochemistry-Paraffin-NBP1-19371-img0012.jpg)
![Immunohistochemistry-Frozen: CD4 Antibody [NBP1-19371] - Staining in mouse liver tissue.](http://images.novusbio.com/fullsize/CD4-Antibody-Immunohistochemistry-Frozen-NBP1-19371-img0013.jpg)
![Immunohistochemistry-Paraffin: CD4 Antibody [NBP1-19371] - Alcohol-fixed paraffin-embedded rat spleen tissue. Dilution 1:150. Image from verified customer review.](http://images.novusbio.com/fullsize/CD4-Antibody-Immunohistochemistry-Paraffin-NBP1-19371-img0014.jpg)
![Flow Cytometry: CD4 Antibody [NBP1-19371] - An intracellular stain was performed on Jurkat cells with CD4 Antibody NBP1-19371R (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 550.](http://images.novusbio.com/fullsize/CD4-Antibody-Flow-Cytometry-NBP1-19371-img0015.jpg)
![Flow Cytometry: CD4 Antibody [NBP1-19371] - An intracellular stain was performed on Jurkat cells with CD4 Antibody NBP1-19371AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/CD4-Antibody-Flow-Cytometry-NBP1-19371-img0016.jpg)
![Flow Cytometry: CD4 Antibody [NBP1-19371] - An intracellular stain was performed on U937 cells with CD4 Antibody NBP1-19371AF594 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 594.](http://images.novusbio.com/fullsize/CD4-Antibody-Flow-Cytometry-NBP1-19371-img0021.jpg)
![Flow Cytometry: CD4 Antibody [NBP1-19371] - An intracellular stain was performed on U937 cells with CD4 Antibody NBP1-19371G (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 488.](http://images.novusbio.com/fullsize/CD4-Antibody-Flow-Cytometry-NBP1-19371-img0022.jpg)
![Simple Western: CD4 Antibody [NBP1-19371] - Lane view shows a specific band for CD4 in 0.5 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/CD4-Antibody-Simple-Western-NBP1-19371-img0009.jpg)
![Dual RNAscope ISH-IHC: CD4 Antibody [NBP1-19371] - IFNG mRNA (red) and CD4 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human lung cancer. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-IFNG and CD4 antibody at 1:100 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin (Cat. No. DS9800), BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/CD4-Antibody-Dual-RNAscope-ISH-IHC-NBP1-19371-img0019.jpg)
![Dual RNAscope ISH-IHC: CD4 Antibody [NBP1-19371] - CCR5 mRNA (red) and CD4 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human lung cancer. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-CCR5 and CD4 antibody at 1:100 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/CD4-Antibody-Dual-RNAscope-ISH-IHC-NBP1-19371-img0020.jpg)
![Immunocytochemistry/ Immunofluorescence: CD4 Antibody - BSA Free [NBP1-19371] - Rats with mild liver damage show immune cells infiltration in cerebellum at 4 weeks, which is prevented by rifaximin. Analysis of immune cells infiltration in cerebellum was performed at 4 weeks by immunohistochemistry using antibodies against (A) CD4, a marker of T lymphocytes (F(3,8) = 4.511, p < 0.01) & (B) IBA1, a marker of meningeal & perivascular macrophages (K-W(4,10) = 27.76, p < 0.0001). (C) Double immunofluorescence with anti-CD4 & anti-CX3CR1 as markers of autoreactive CD4+CD28− T lymphocytes was performed & quantified (K-W(4,5) = 8.711, p < 0.05). (D) Double immunofluorescence with anti-CD4 & anti-CCR6 as marker of Th17 lymphocytes was performed & quantified (K-W(4,7) = 8.858, p < 0.05). Number of animals in each group was added under group names. One-way ANOVA with Tukey’s test (CD4+) & nonparametric Kruskal–Wallis (K-W statistic) with Dunn’s test (Iba1, CD4+/CX3CR1+ & CD4+/CCR6+) was performed to compare all groups. Values significantly different from control rats are indicated by asterisks & from CCl4 rats by a. * p < 0.05, a p < 0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/34440206), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-19371_rabbit-polyclonal-cd4-antibody-310202416163759.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - Validation with PD-L1 siRNA Knockdown. HeLa cells were transfected with control siRNAs (lane 1) or PD-L1 siRNAs (lane 2). Loading: 10 ug of HeLa whole cell lysates per lane. Antibodies: NBP1-76769 (2 ug/mL) and GAPDH (0.02 ug/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Knockdown-Validated-NBP1-76769-img0024.jpg "<b>Genetic Strategies Validation. </b>Western Blot: PD-L1 Antibody [NBP1-76769] - Validation with PD-L1 siRNA Knockdown. HeLa cells were transfected with control siRNAs (lane 1) or PD-L1 siRNAs (lane 2). Loading: 10 ug of HeLa whole cell lysates per lane. Antibodies: NBP1-76769 (2 ug/mL) and GAPDH (0.02 ug/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.")
![<b>Independent Antibodies Validation and Genetic Strategies Validation.</b>Western Blot: PD-L1 Antibody [NBP1-76769] - Independent Antibody Validation (IAV) via Protein Expression ProfileLoading: 15 ug of lysates per lane.Antibodies: NBP1-76769 (2 ug/mL), PD-L1 (2 ug/mL), and beta-actin (1 ug/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit and or anti-mouse IgG HRP conjugate at 1:10000 and 1:5000 dilution, respectively.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0023.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - CD274 (PD-L1) expression in the HNSCC patients from the TCGA database , HNSCC tissue samples and the HNSCC cells. Immunostaining of PD-L1 obtained from HNSCC tumor cells, immune cells and tumor margin tissues in HNSCC tissue samples (magnification A-200, scale bars 50AI1/4m) : low tumor staining; moderate tumor staining; high tumor staining have been observed. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-Negative-NBP1-76769-img0025.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - PD-L1 expression was evaluated in gastric cancer cells. Levels of PD-L1 protein were assessed in normal human gastric epithelial cells and 8 gastric cancer cell lines by Western blots. Image collected and cropped by Citeab from the following publication (Autophagy inhibition enhances PD-L1 expression in gastric cancer. J Exp Clin Cancer Res (2019)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0026.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: PD-L1 Antibody [NBP1-76769] - Upregulated expression of PD-L1 in cisplatin-resistant cells through IL-6/STAT3. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0027.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - CD274 (PD-L1) expression in the HNSCC patients from the TCGA databas HNSCC cells. CD274 expression with survival and its relation with therapy in the HNSCC patients from the TCGA database. Expression of CD274 gene and PD-L1 protein in the established cisplatin-resistant HNSCC cells and cisplatin sensitive cells by qRT-PCR and WB (F, H): CD274 (PD-L1) expressed in cisplatin resistant cell. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0028.jpg)
![Immunocytochemistry/Immunofluorescence: PD-L1 Antibody [NBP1-76769] - U-251 MG cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NBP1-76769 at 1 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-76769-img0029.jpg)
![Flow Cytometry: PD-L1 Antibody [NBP1-76769] - An intracellular stain was performed on U-251 MG cells with PD-L1 Antibody NBP1-76769 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/PD-L1-Antibody-Flow-Cytometry-NBP1-76769-img0030.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - Expression of CD274 in Human melanoma SK-MEL-28 cell line upon treatment with 200 mM ethanol. Dilution: 1:1,000 in PBS with 5% BSA. Secondary Ab: anti-Rabbit IgG 1:5,000. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0019.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - B7-H1/PD-L1/CD274 Antibody [NBP1-76769] - Human tonsil tissue with PD-L1 antibody at 5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0017.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - Staining of human heart tissue with antibody at 2.5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0010.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - PD-L1/B7-H1 Antibody [NBP1-76769] - PD-L1 in rat heart tissue with at 5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0020.jpg)
![Flow Cytometry: PD-L1 Antibody [NBP1-76769] - B7-H1/PD-L1/CD274 Antibody [NBP1-76769] - Analysis of A-20 cells using B7-H1/PD-L1/CD274 antibody at 0.5 ug/mL. Green: Isotype control. Red : B7-H1/PD-L1/CD274 antibody.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Flow-Cytometry-NBP1-76769-img0018.jpg)
![Immunofluorescence: PD-L1 Antibody [NBP1-76769] - Human Heart cells with PD-L1 antibody at 20 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunofluorescence-NBP1-76769-img0009.jpg)
![Dual RNAscope ISH-IHC: PD-L1 Antibody [NBP1-76769] - PDCD1 mRNA (red) and PD-L1 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human lung cancer. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-PDCD1 and PD-L1 antibody at 1:100 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/PD-L1-Antibody-Dual-RNAscope-ISH-IHC-NBP1-76769-img0031.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ROS mediated PD-L1 upregulation in FFA-treated LO2 cells. (a) Intracellular ROS in LO2 cells before & after FFA treatment measured by DCFH-DA. (b–d) Expression levels of NOX2 & NOX4 measured using qRT-PCR & western blot. (e) JC-1 probes were used to detect mitochondrial membrane potential. (f–j) Intracellular ROS in LO2 cells pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment, measured by DCFH-DA, PD-L1 expression determined by western blot. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415382415.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-31020241534538.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 expression levels in liver samples & FFA-treated LO2 cells. (a–d) PD-L1 expression & CD8+ T cells in the liver tissues determined by immunohistochemistry. (e) Intracellular lipid accumulation after FFA treatment (0.8 mM) for 24 hour measured by Oil Red staining. (f–i) Expression levels of PD-L1 detected by qRT-PCR, western blot, & immunofluorescence. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415175299.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415291978.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415175210.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ROS/ZNF24/PD-L1 pathway activation in NAFLD models. (a) Intracellular ROS in hepatocytes in NAFLD significantly increased. (b) JC-1 probes were used to detect mitochondrial membrane potential. (c & d) NOX4 & ZNF24 expressions were determined by immunohistochemistry. (e & f) ROS/ZNF24/PD-L1 pathway activation examined by western blot. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415284517.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 limits liver injury in NAFLD models. (a & b) Western blot determined the effect of siRNA against PD-L1. (c) After PD-L1 knockdown, mRNA expression levels of markers of T cell activation measured by qRT-PCR. (d & e) Hepatocyte injury was evaluated by the Tunel assay & ALT/AST measurement. (f) Graph illustrating that both ROS/ZNF24 pathway activation & UBE2I-mediated ZNF24 sumoylation suppression induced by FFA promoted PD-L1 expression. ∗P < 0.05, ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-31020241529331.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 knockdown aggravated the damage of CD8 + T cells to FFA-treated LO2 cells. (a & b) Western blot determined the effect of siRNA against PD-L1. Coculturing of FFA-treated LO2 cells & CD8 + T cells in vitro. (c) mRNA expression levels of markers of T cell activation measured by qRT-PCR, (d) LO2 cell injury was evaluated by LDH assay, (e) AST or ALT in the supernatants measured by commercial assay kits. # represents that CD8 + T cells were incubated separately with LO2 cells, but supernatants were put together. ∗P < 0.05, ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415304228.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Upregulated expression of PD‐L1 in cisplatin‐resistant cells through IL‐6/STAT3. The cisplatin resistant CAL27cis & Detroit‐562cis cells had increased IL‐6 mRNA & IL‐6 protein production compared to parental cells by qRT‐PCR & ELISA (A, B). CAL27cis & Detroit‐562cis were cultured with IL‐6 (10 ng/mL, human recombinant IL‐6, R&D Systems, Minneapolis, USA) for 48 h (C). An anti‐human IL‐6 polyclonal antibody (R&D Systems, Minneapolis, USA) was used to neutralize the biological activities of IL‐6 (E, F). To inhibit signal transduction, CAL27cis & Detroit‐562cis cells were pre‐incubated for 1 h with STAT3 inhibitor V (Sigma‐Aldrich, Germany, 500 nmol/L), & then incubated with recombinant human IL‐6 (10 ng/mL) for 24 h before analysis. Data are shown as mean ± SD of 3 independent triplicate cultures (A, B, D, E, F, H). *P < .05, **P < .01 & ***P < .001, compared with the results of control without IL‐6 (D), control IgG (E, F) & with IL‐6 alone (H) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29761938), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175266.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ZNF24 promoted PD-L1 expression through binding to its promoter in FFA-treated LO2 cells. (a) A schematic of the target sites (wild & mutant) of ZNF24 in the promoter of PD-L1. (b–d) Dual-luciferase reporter assays performed in LO2 cells transfected with WT or MT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression. (e–g) ZNF24 expression after FFA treatment determined by qRT-PCR & western blot. (h & i) ZNF24 expression in LO2 cells pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment, measured by western blot. (j & k) ZNF24 & PD-L1 expression in LO2 cells pretreated with siRNA against ZNF24, followed by FFA treatment detected by western blot. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416165623.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - LfcinB reduced IL‐6‐dependent PD‐L1 expression in cisplatin‐resistant HNSCC cells (A‐C) & inhibited the xenograft growth from CAL27cis & Detroit‐562cis (D, E). The markedly decreased IL‐6 (A) by ELISA & PD‐L1 by WB (B, C) in the acquired cisplatin‐resistant cells were detected. In figure A, C & D, data are shown as mean ± SD of 3 independent triplicate cultures. *P < .05 & **P < .01, compared with the results of control without IL‐6 (A, C). To investigate the effects of LfcinB on in vivo growth of CAL27cis & Detroit‐562cis, we treated nude mice carrying CAL27cis (D) & Detroit‐562cis (E) xenografts with once‐daily injection of 0.75 mg LfcinB (n = 5). Tumor growth of HNSCC xenografts displayed significant reduction after 3 days of LfcinB treatment, compared to control with saline (*P < .05 for LfcinB) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29761938), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175227.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Identification of ZNF24–UBE2I protein interactions. (a & b) Analysis of protein interactions between ZNF24 & UBE2I using the BioGRID database, further confirmed by Co-IP assays. (c–f) UBE2I expression in LO2 cells treated by FFA or pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment measured by western blot. (g & h) After FFA treatment, Sumo-1: ZNF24 & ZNF24 expression levels detected by western blot. (i & j) After UBE2I overexpression, Sumo-1: ZNF24, ZNF24, PD-L1, & UBE2I expression levels were determined by western blot. (k–m) Dual-luciferase reporter assays performed in LO2 cells transfected with WT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression with or without Sumo-1 overexpression. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175269.jpg)
![Immunohistochemistry-Paraffin: CD3 Antibody (SP7) [NB600-1441] - FFPE human tonsil stained with CD3 antibody.](http://images.novusbio.com/fullsize/CD3-Antibody-SP7-Immunohistochemistry-Paraffin-NB600-1441-img0001.jpg "Immunohistochemistry-Paraffin: CD3 Antibody (SP7) [NB600-1441] - FFPE human tonsil stained with CD3 antibody.")
![Immunohistochemistry-Frozen: CD3 Antibody (SP7) [NB600-1441] - T-cells and microglia in mouse spinal cord with acute EAE. Mouse was perfused with 4% paraformaldehyde. Spinal cord was post-fixed overnight, followed by cryoprotection with 30% sucrose for 24h. Spinal cord sections were treated with antigen-retrieval buffer (pH 6.0) at 60C for 10 min, then cooled down to room temperature (this step should not be omitted). Anti-CD3 antibody was diluted at 1:200. Incubation: room temperature overnight. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD3-Antibody-SP7-Immunohistochemistry-Frozen-NB600-1441-img0002.jpg)
![<b>Genetic Strategies Validation. </b>Immunohistochemistry-Paraffin: CD3 Antibody (SP7) [NB600-1441] - Mouse lung tissue stained against C3aR normal conditions (left) and knockdown conditions (right). IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD3-Antibody-SP7-Immunohistochemistry-Paraffin-NB600-1441-img0003.jpg)
![Immunohistochemistry-Paraffin: CCR7 Antibody [NB100-712] - M1 and M2 macrophages showed similar expression patterns in cortical bone. IHC staining was performed in sagittal serial sections of medial condyles from 6-week-old rats within the diaphyseal region. Cluster of differentiation 68 (CD68) was selected as a pan marker for the macrophage lineage, including monocytes, macrophages, giant cells, and osteoclasts. iNOS and C-C chemokine receptor type 7 (CCR7) were selected as M1 phenotypic markers, whereas Arginase1 and cluster of differentiation 163 (CD163) were selected as M2 phenotypic markers. Tartrate-resistant acid phosphatase (TRAP) staining was performed as described in Materials and Methods. Quantification of cell numbers according to their location revealed that most of the M1 and M2 cells were not attached to the bone surfaces. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/boneres201719) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCR7-Antibody-Immunohistochemistry-Paraffin-NB100-712-img0006.jpg "Immunohistochemistry-Paraffin: CCR7 Antibody [NB100-712] - M1 and M2 macrophages showed similar expression patterns in cortical bone. IHC staining was performed in sagittal serial sections of medial condyles from 6-week-old rats within the diaphyseal region. Cluster of differentiation 68 (CD68) was selected as a pan marker for the macrophage lineage, including monocytes, macrophages, giant cells, and osteoclasts. iNOS and C-C chemokine receptor type 7 (CCR7) were selected as M1 phenotypic markers, whereas Arginase1 and cluster of differentiation 163 (CD163) were selected as M2 phenotypic markers. Tartrate-resistant acid phosphatase (TRAP) staining was performed as described in Materials and Methods. Quantification of cell numbers according to their location revealed that most of the M1 and M2 cells were not attached to the bone surfaces. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/boneres201719) licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: CCR7 Antibody [NB100-712] - Mouse spleen](http://images.novusbio.com/fullsize/CCR7-Antibody-Immunohistochemistry-Paraffin-NB100-712-img0001.jpg)
![Immunohistochemistry-Paraffin: CCR7 Antibody [NB100-712] - Mouse spleen](http://images.novusbio.com/fullsize/CCR7-Antibody-Immunohistochemistry-Paraffin-NB100-712-img0004.jpg)
![Immunohistochemistry-Paraffin: CCR7 Antibody [NB100-712] - Human spleen](http://images.novusbio.com/fullsize/CCR7-Antibody-Immunohistochemistry-Paraffin-NB100-712-img0005.jpg)
![Immunohistochemistry: CCR7 Antibody [NB100-712] - M1 expression pattern changed in trabecular bone. Immunohistochemical staining was performed in sagittal serial sections of medial condyles from 6-week-old rats within the epiphyseal region. The region with the solid line indicates areas of interest to be enlarged in the following image. Representative staining with the anticluster of differentiation 68 (CD68) antibody demonstrated that CD68+ cells were either attached (black arrows) or unattached (white arrows) to the bone surfaces with a variety of sizes & shapes (a, b). TRAP+ cells showed multinucleated morphology (black arrows) which is similar to the CD68+ cells (c, d). Inducible nitric oxide synthase-positive (iNOS+) & C-C chemokine receptor type 7-positive (CCR7+) cells (black arrow) were attached to the bone surfaces with an elongated morphology (e, f, i, j). Arginase1+ & cluster of differentiation 163-positive (CD163+) cells (white arrow) represented the predominant population in the reticular connective tissue with similar expression patterns as in the cortical bone (g, h, k, l). No positive staining was found in isotype controls (data not shown). Most of the M1-labeled cells were found attached to bone surfaces instead of M2-labeled cells (m). Representative images from three independent experiments are shown. FOV, field of view. Data shown as the mean±s.d. (*P<0.05). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29263936), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-712_goat-polyclonal-ccr7-antibody-310202415532041.jpg)
![Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - In vitro nephrotoxicity assessment of kidney spheroids. Western blotting analysis of kidney injury markers in kidney spheroids after treatment with 20 uM cisplatin (CPT) or 50 uM cisplatin cyclosporin A (CSA). All data are shown as the means +/- s.e.m. *p < 0.05 compared with control by unpaired Student's t-test. Scale bar, 20 um. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/s41598-019-53855-2) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0016.jpg "<b>Biological Strategies Validation. </b>Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - In vitro nephrotoxicity assessment of kidney spheroids. Western blotting analysis of kidney injury markers in kidney spheroids after treatment with 20 uM cisplatin (CPT) or 50 uM cisplatin cyclosporin A (CSA). All data are shown as the means +/- s.e.m. *p < 0.05 compared with control by unpaired Student's t-test. Scale bar, 20 um. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/s41598-019-53855-2) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Paraffin: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - Analysis of human uterus tissue using anti-TIM-1 antibody (3809) at 10 ug/ml.Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4 C. A goat anti-rabbit IgG H&L (HRP)at 1/250 was used as secondary. Counter stained with Hematoxylin.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Immunohistochemistry-Paraffin-NBP1-76701-img0013.jpg)
![Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - Loading: 15 ug of NIH/3T3 cell lysates. Antibodies: TIM-1 3809 (8 ug/mL), overnight incubation at 4 C in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0010.jpg)
![<b>Independent Antibodies Validation. </b>Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - Loading: 15 ug of lysates per lane. Antibodies: TIM-1 3809 (8 ug/mL), TIM-13811 (1 ug/mL), beta-actin (1 ug/mL), and GAPDH (0.02 ug/mL), overnightincubation at 4C (3809) or 1h incubation at RT in 5% NFDM/TBST. Secondary:Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0012.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - HeLa cells were transfected with control siRNAs (lane 1) or TIM-1 siRNAs (lane 2) Loading: 15 ug of HeLa whole cell lysates per lane. Antibodies: 3809 (8 ug/mL), 1 hincubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0015.jpg)
![Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - Figure 1 Western Blot Validation in Human Cell LinesLoading: 15 u of lysates per lane.Antibodies: TIM-1 (8 u/mL), overnight incubation at 4; C in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/nbp1-76701_rabbit-polyclonal-tim-1-kim-1-havcr-antibody-2711202420171718.gif)
![Immunocytochemistry/ Immunofluorescence: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - Validation of TIM-1/KIM-1/HAVCR in Human Uterus Cells. Immunofluorescent analysis of 4% paraformaldehyde-fixed human uterus cells labeling TIM-1/KIM-1/HAVCR with at 20 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red). Image showing both membrane and cytoplasmic staining on human uterus cells.](http://images.novusbio.com/fullsize/nbp1-76701_rabbit-polyclonal-tim-1-kim-1-havcr-antibody-271120241937768.jpg)
![Western Blot: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Western blot shows lysates of Ramos human Burkitt's lymphoma parental cell line and B7-2 knockout (KO) Ramos cell line. PVDF membrane was probed with 1.0 ug/mL of Mouse Anti-Human B7-2 Monoclonal Antibody (Catalog # NBP2-25208) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #HAF018). Specific band was detected for B7-2 at approximately 90 kDa (as indicated) in the parental Ramos cell line, but is not detectable in the knockout Ramos cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/B7-2-CD86-Antibody-BU63-Knockout-Validated-NBP2-25208-img0005.jpg "<b>Genetic Strategies Validation. </b>Western Blot: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Western blot shows lysates of Ramos human Burkitt's lymphoma parental cell line and B7-2 knockout (KO) Ramos cell line. PVDF membrane was probed with 1.0 ug/mL of Mouse Anti-Human B7-2 Monoclonal Antibody (Catalog # NBP2-25208) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #HAF018). Specific band was detected for B7-2 at approximately 90 kDa (as indicated) in the parental Ramos cell line, but is not detectable in the knockout Ramos cell line. This experiment was conducted under reducing conditions.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Macrophage polarization states. Distribution and proportion of CD86+ macrophages (brown) were identified using IHC procedures. Intensity for the color response to antibodies was visible in lung tissues from all groups. Population proportions for the stained cells as shown by red arrows were calculated as a fold change of the control. (d). The results were expressed as Mean +/- SD (n = 3). **: a p-value of < 0.01 vs NS, OVA/BUD and OVA/PCI except the number of CD86+ cells in OVA/PCI group. #: P < 0.05 vs NS and ##; P < 0.01 vs either NS or OVA/BUD group. Image collected and cropped by CiteAb from the following publication (//respiratory-research.biomedcentral.com/articles/10.1186/s12931-020-1322-5) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/B7-2-CD86-Antibody-BU63-Immunohistochemistry-NBP2-25208-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Immunofluorescence staining of PFA-fixed Ramos cells using followed by goat anti-Mouse IgG conjugated to CF488 (green). Nuclei are stained with Red Dot.](http://images.novusbio.com/fullsize/B7-2-CD86-Antibody-BU63-Immunocytochemistry-Immunofluorescence-NBP2-25208-img0006.jpg)
![Immunohistochemistry: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Effects of 20(S)-Rg3 on macrophage polarization in atherosclerotic lesions of diabetic ApoE-/- mice. Co-immunofluorescence staining for macrophage (anti-Moma-2 antibody, green), M1 marker CD86 (red) and DAPI (blue) (n = 5, respectively). Scale bar: 20 um. Image collected and cropped by CiteAb from the following publication (//www.frontiersin.org/articles/10.3389/fphar.2018.00464/full) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/B7-2-CD86-Antibody-BU63-Immunohistochemistry-NBP2-25208-img0010.jpg)
![Flow Cytometry: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Flow Cytometric Analysis of PFA-fixed Ramos cells. B7-2/CD86 Antibody (BU63) followed by goat anti-Mouse IgG-CF488 (Blue); Isotype Control (Red).](http://images.novusbio.com/fullsize/B7-2-CD86-Antibody-BU63-Flow-Cytometry-NBP2-25208-img0008.jpg)
![Immunohistochemistry-Paraffin: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Formalin-fixed, paraffin-embedded esophagus tumor tissue stained with CD86 antibody (5 ug/ml), peroxidase-conjugate and DAB chromogen. Note strong staining of differentiated squamous cells. TMA was used for this test.](http://images.novusbio.com/fullsize/B7-2-CD86-Antibody-BU63-Immunohistochemistry-Paraffin-NBP2-25208-img0004.jpg)
![Flow Cytometry: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Flow Cytometric Analysis of human PBMCs using B7-2/CD86 Antibody (BU63); Goat anti-Mouse IgG-CF488 (red); Isotype Control (green).](http://images.novusbio.com/fullsize/B7-2-CD86-Antibody-BU63-Flow-Cytometry-NBP2-25208-img0007.jpg)
![Immunohistochemistry: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Macrophage polarization states. Distribution & proportion of CD68+ (a), CD86+ (c) & CD163+ (e) macrophages (brown) were identified using IHC procedures. Intensity for the color response to antibodies was visible in lung tissues from all groups. Population proportions for the stained cells as shown by red arrows were calculated as a fold change of the control. (b, d, f). The results were expressed as Mean ± SD (n = 3). **: a p-value of < 0.01 vs NS, OVA/BUD & OVA/PCI except the number of CD86+ cells in OVA/PCI group. #: P < 0.05 vs NS & ##; P < 0.01 vs either NS or OVA/BUD group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32111211), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-25208_mouse-monoclonal-b7-2-cd86-antibody-bu63-imgenex-img-6882a-25ug-31020241534324.jpg)
![Immunocytochemistry/ Immunofluorescence: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Effects of 20(S)-Rg3 on macrophage polarization in atherosclerotic lesions of diabetic ApoE–/– mice. (A,B) Co-immunofluorescence staining of the aortic root for macrophage (anti-Moma-2 antibody, green) & M1 marker iNos (red), & a bar graph summarizing the results (n = 5, respectively). (C,D) Co-immunofluorescence staining for macrophage (anti-Moma-2 antibody, green) & M1 marker CD86 (red), & a bar graph summarizing the results (n = 5, respectively). Scale bar: 20 μm. Data are mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29867472), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-25208_mouse-monoclonal-b7-2-cd86-antibody-bu63-imgenex-img-6882a-25ug-31020241535650.jpg)
![M1 macrophages were induced in the in vivo mouse intervertebral disc (mIVD) degeneration model (puncture model). (a) Immunohistological analysis of Iba-1, iNOS, and arginase (brown staining) expression in nucleus pulposus (NP), annulus fibrosis (AF), and cartilage endplate (CEP) [right] at high magnification and in whole mIVDs (left) at low magnification. Images using an IgG isotype control antibody are included to demonstrate the specificity of the IHC staining. (b) Protein was extracted from punctured mIVDs in the puncture model, and western blotting was performed using antibodies against CD86, CD163, and beta -actin. (c) Images of the panel in (b), captured using a ChemiDoc Touch system and quantified using ImageJ. Biological and technical replicates were performed three times. Values represent the mean +/- SD. *p < 0.05, **p < 0.01, relative to the corresponding control. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/41053148), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-25208_mouse-monoclonal-b7-2-cd86-antibody-bu63-western-blot-13220261327102.jpg)
![Flow Cytometry: IL-7 R alpha/CD127 Antibody (R34-34) [DDX0700P-100] - Facs staining of PBL with R34-34](http://images.novusbio.com/fullsize/IL-7-R-alpha-CD127-Antibody-R34-34-Flow-Cytometry-DDX0700P-100-img0003.jpg "Flow Cytometry: IL-7 R alpha/CD127 Antibody (R34-34) [DDX0700P-100] - Facs staining of PBL with R34-34")
![Flow Cytometry: IL-7 R alpha/CD127 Antibody (R34-34) [DDX0700P-100] - Facs staining of R34-34-transfected Cos7 cells](http://images.novusbio.com/fullsize/IL-7-R-alpha-CD127-Antibody-R34-34-Flow-Cytometry-DDX0700P-100-img0002.jpg)
![Immunoprecipitation: IL-7 R alpha/CD127 Antibody (R34-34) [DDX0700P-100] - R34-34 antigen from 125I-surface labelled Pre-Alp cells](http://images.novusbio.com/fullsize/IL-7-R-alpha-CD127-Antibody-R34-34-Immunoprecipitation-DDX0700P-100-img0001.jpg)